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ABSTRACT
Introduction: Psoriasis is a common chronic
disease with significant impairment in quality
of life. As there is no cure, it often requires
lifelong disease control to minimize the
development of skin lesions and to relieve
symptoms. The aim of this publication is to
systematically review the role of currently used
emollients and keratolytics in the treatment of
psoriasis.
Methods: A systematic literature search was
conducted in Medline via PubMed regarding
reviews, meta-analyses, and trials published
from January 1983 to December 2013 dealing
with topical administration of emollients and
keratolytics in patients with psoriasis. A
subsequent search in EMBASE regarding
clinical trials published from 1983 to 2013 was
performed to complement the findings.
Results: A total of 60 publications met the
inclusion criteria for full-text evaluation. While
current reviews, meta-analyses, and guidelines
state that adjuvant therapy with emollients and
keratolytics should be an obligatory part in the
therapy of psoriasis to facilitate descaling
and/or penetration enhancement,
comprehensive trials on these agents are
missing, with the exception of combination
products containing salicylic acid and
corticosteroids. In the mentioned trials,
addition of salicylic acid was beneficial in
inducing a more rapid onset of action as well
as a reduction of severity parameters and the
area affected. However, its use has substantial
limitations in young children, in patients with
renal/hepatic impairment, with widespread
psoriasis, those undergoing phototherapy, or
those concomitantly treated with
calcipotriene/systemic salicylates.
Conclusion: In view of these shortcomings,
there is a need for well-designed studies on
suitable keratolytic alternatives to salicylic acid
offering an indisputable positive benefit–risk
ratio.
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INTRODUCTION
Psoriasis is a chronic, immune-mediated,
inflammatory, systemic disease with
predominant skin and joint manifestations. As
such, it has significant implications on physical,
psychological, and social functioning [1–8].
Psoriasis represents one of the most common
chronic inflammatory diseases worldwide,
affecting approximately 2–3% of the
population [4, 5, 7, 9–11]. About 80–90% of
patients with psoriasis have the plaque form of
the disease [3, 10]. Although the majority of
psoriatic cases are mild to moderate in severity,
approximately 20% of patients suffer from
moderate to severe disease as determined by
the percentage of body surface area involved or
the overall degree of erythema, induration, and
desquamation [3]. The impairment in quality of
life due to psoriasis has been found to be
equivalent to that from major systemic diseases
such as arthritis, type 2 diabetes, chronic lung
disease, and myocardial infarction [1, 10, 12].
Currently, topical treatments with
corticosteroids and vitamin D analogs
represent first-line therapies for psoriasis [13].
Topical treatments may also employ calcineurin
inhibitors, dithranol, tazarotene, or tar [14]. In
patients with more severe or treatment-resistant
disease, second- or third-line therapies include
phototherapy, systemic agents such as
methotrexate, and, more recently, biologicals
such as tumor necrosis factor inhibitors. These
therapeutic modalities have been proven to be
highly effective; however, the potential for
long-term toxicity needs to be considered [13].
Phototherapy includes narrow-band ultraviolet
(UV) B, broadband UVB, as well as psoralen and
UVA photochemotherapy [15, 16].
Patient surveys have revealed that, at
present, patients do not receive optimal
treatments and experience insufficient
satisfaction with the efficacy of available
topical treatments as reflected by a high rate
of non-compliance [17–19]. Since in a cyclical
pattern, treatment outcome influences
treatment satisfaction, which in turn affects
medication adherence; the effectiveness of
topical treatments may be improved by
increasing patients’ adherence [18]. Therefore,
and since psoriasis often requires lifelong
therapy, safe, convenient, and effective topical
regimens with good cosmetic acceptance can be
of great benefit in this large patient population
[20].
Current guidelines recommend keratolytics
such as topical preparations containing urea
and salicylic acid as adjuvant therapy for
psoriasis and state that these represent an
internationally recognized standard in the
treatment of all severity states of psoriasis [10].
The claimed benefits of these agents are
specified in Table 1 [3, 4, 6, 21–23].
However, profound and recent evidence on
their efficacy from clinical trials is lacking.
Therefore, the aim of this publication is to
systematically review the role of currently used
emollients and keratolytics in the treatment of
psoriasis to answer the following questions:
• What do authors of recently published
reviews/meta-analyses conclude on the role
of emollients and keratolytics in the
treatment of psoriasis?
• What is the current evidence from clinical
trials on these agents with respect to efficacy
and safety that has been published during
the last 30 years?
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METHODS
Systematic literature searches were performed in
Medline and EMBASE. Literature searches for
relevant articles published within the last
20 years were conducted on December 30,
2013 in Medline via PubMed using the
following search term: ‘‘(1993/01/01:2013/11/
30[dp] OR 1993/01/01:2013/11/30[edat]) AND
psoriasis AND (keratolysis OR keratolytic OR
salicylic acid OR urea)’’. The results were further
confined using specific qualifier words
regarding efficacy, safety, or type of
publication, for example, ‘‘therapeutic use’’,
‘‘efficacy’’, ‘‘effectiveness’’, ‘‘safety’’,
‘‘tolerability’’, ‘‘toxicity’’, ‘‘review’’, ‘‘meta-
analysis’’, ‘‘practice guideline’’, ‘‘clinical trial’’,
or ‘‘randomized controlled trial’’. The search
yielded a total of 798 articles for consideration.
All hits were reviewed based on abstracts and/or
Medical Subject Headings (MeSH) terms.
Articles that did not specifically deal with the
safety and efficacy of emollients or keratolytics
in the treatment of psoriasis but dealt with
other psoriasis treatments such as hydroxyurea
or topical retinoids, with other indications or
other topics or subjects (e.g., methods papers,
non-clinical, mechanistic studies) were
excluded. This applied to the majority of
retrieved publications (approximately 90%).
Because salicylic acid is frequently added to
dithranol for the prevention of dithranol
oxidation, all publications on the combination
of salicylic acid and dithranol were excluded
[24]. The same applies to efficacy trials
conducted in healthy volunteers or in patients
with disorders other than psoriasis. Whereas
clinical studies investigating keratolytics vs.
baseline, placebo, no treatment, or other
keratolytics and combination therapy vs. the
respective monotherapy without penetration
enhancement were considered eligible for
inclusion, articles that dealt with the safety or
efficacy of conventional keratolytics in
combination therapies for psoriasis but did not
investigate the monosubstances and did thus
not allow drawing conclusions about their
specific effect were not considered
(approximately 2% of hits). Articles that were
not written in English or German were excluded
(approximately 2% of hits). Guidelines or
reviews which had already been revised were
not considered. Since the number of articles
providing evidence on the role of conventional
keratolytics in the therapy of psoriasis
published in the last 20 years was limited, the
search period was extended to the last 30 years.
The searches for relevant literature published
between 1983 and 1993 were conducted in
Medline via PubMed using the following search
terms: ‘‘psoriasis AND (keratolytic[Majr] OR
salicylic acid[Majr] OR urea[Majr])’’, ‘‘psoriasis
AND (keratolysis OR keratolytic) AND (rct OR
randomized controlled trial)’’ and ‘‘psoriasis AND
(salicylates[Majr])’’. Using the above-mentioned
selection criteria, a total of 53 guidelines, meta-
analyses, reviews, and clinical trials published in
German or English language from January 1983
to December 2013 and dealing with topical
administration of keratolytics in patients with
psoriasis were regarded as potentially relevant
Table 1 Main objectives of using keratolytics in psoriasis
Main objectivesa
• Softening/hydration of the stratum corneum
• Desquamation of hyperkeratotic skin
• Relieve of pruritus/discomfort
• Barrier repair
• Penetration enhancement of topically applied
anti-psoriatic drugs/ultraviolet radiation
during phototherapy
a Cited according to published reviews [3, 4, 6, 21–23]
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and selected for full-text assessment. After full-
text review, seven articles were excluded as they
did not refer to emollients or keratolytics (n = 2)
or did not compare combination therapy vs. the
respective monotherapy without penetration
enhancement (n = 5).
Since Medline may not have revealed all
relevant publications (i.e., clinical trials),
additional searches for original literature on
psoriasis published in English or German
language between 1983 and 2013 were
performed in EMBASE using the qualifier
‘‘clinical trial’’ and the controlled terms
‘‘keratolytic agent’’, ‘‘salicylic acid’’, and ‘‘urea’’.
These searches yielded a total of 41 articles for
consideration, of which 3 articles had not
previously been identified in Medline. The
selection was further complemented by
publications that were cited in the articles
identified by the systematic literature searches
and by including relevant current guidelines on
psoriasis treatment as well as references therein
(n = 11).
The results section of this paper consists of
four subsections referring to the group of
emollients and major keratolytic agents, each
starting with a paragraph that contains
information on the mechanism of action and
evidence of the efficacy and safety as extracted
from reviews, meta-analyses, and/or guidelines.
This information is followed by the data on
efficacy and safety derived from published
clinical trials. This review is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
From systematic literature searches conducted
in Medline via PubMed and EMBASE, a total of
49 publications met the inclusion criteria for
this review. Furthermore, the reference lists of
included publications were scrutinized for
additional studies published in January 1983
or later, adding 11 publications to the selection.
Thus, a total of 60 publications were reviewed.
Emollients
Emollients induce an occlusive film that limits
evaporation of water from deeper parts of the
skin and allows the stratum corneum to
rehydrate itself. The application of natural
moisturizing factors induces an increase in the
water-binding capacity of the stratum corneum
[21]. Regular application of emollients improves
comfort and reduces scaling, fissuring [1], and
itching in patients with plaque or scalp psoriasis
[25, 26]. Additionally, emollients may increase
the efficacy of topical corticosteroids by
improving the penetration through the skin
layers [21, 27, 28]. Guidelines of care for the
management of psoriasis and psoriatic arthritis
state that when used as a control in topical
steroid trials, non-medicated topical
moisturizers demonstrated a response rate
ranging from 15 to 47% [21, 27]. This broad
range may reflect the great variability of their
composition; however, in the corresponding
guideline dealing with topical therapies, the
individual composition of the moisturizers has
not been specified [7]. Emollients are usually
well tolerated [23]. However, they can cause
side effects such as irritant dermatitis, allergic
contact dermatitis, fragrance allergy or allergy
to other constituents, stinging, cosmetic acne,
and pigmentary disorders [21]. In addition,
some reports indicate a potential penetration-
enhancing effect of the stratum corneum to
irritants after long-term use [21]. In clinical and
experimental settings it has been shown that
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some emollients, e.g., oil-in-water emollient
enhance the penetration of UVA or UVB when
used before irradiation, thus increasing the
efficacy of phototherapy [29, 30]. However,
in vitro studies and studies in healthy
volunteers also demonstrated a blocking effect
of other emollients, such as white petrolatum
[31] and the emollient cream Eucerin
(Beiersdorf Inc., Wilton, CT, USA), consistent
with their thickness [32].
While 3 small clinical trials including a total
of 111 patients provide limited evidence that,
compared to baseline, emollients used as a
monotherapy may improve skin hydration,
barrier function, as well as proliferation and
differentiation markers in patients with
psoriasis [11, 33, 34], the clinical response
showed only a slight symptomatic
improvement of psoriasis [33]. Due to
inconsistent results from randomized
controlled trials, there is limited evidence of a
steroid-sparing effect of emollients when used
in combination with corticosteroids. In the
evaluated studies, only two adverse events of
pruritus and folliculitis (each n = 1) were
reported (see Table 2) [11, 33–37].
Urea
Urea is known to exert proteolytic, keratolytic,
hydrating, hygroscopic, penetration-
enhancing, epidermis-thinning, and anti-
pruritic effects. The moisturizing action of
urea in dry and scaly skin conditions has been
widely studied and is well accepted [21, 38].
Fluhr et al. [21] suggested that lipid biosynthesis
may be increased by topical application of
highly concentrated urea. In vitro and in vivo
data showed a reduction of DNA synthesis in
the cells of the basal layers (by approximately
45%), a thinning of the epidermis (by
approximately 20%), a reduction of the
epidermal cells, and a prolongation of the
generation time of postmitotic epidermal cells
[21, 39]. Therefore, urea has been shown to
reduce epidermal hyperproliferation and to
induce cell differentiation [27]. As a
mechanism of action it has been hypothesized
that urea may break hydrogen bonds and
interfere with the quaternary structure of
keratin thus dispersing and denaturizing
keratin without disrupting the epidermal water
barrier. Pre-treatment or concomitant
treatment with urea may also enhance the
efficacy of other topical therapies [39]. Due to
its safety, urea-containing preparations
represent the standard in the adjuvant therapy
of juvenile psoriasis [5]. Only non-systemic side
effects have been reported, with mild irritation
being the most common, making urea a safe
and well-tolerated topical drug [39].
While a small, older comparative study
found no statistical differences on severity
parameters such as scaling, erythema, and
infiltration compared to the vehicle [40], in
another trial using the same preparation,
treatment for 1 week led to a statistically
significant improvement of scaling compared
to the vehicle (see Table 3) [38, 40–46]. This is in
line with two further studies in which severity
parameters of psoriasis such as scaling and/or
induration were reduced with urea in
monotherapy [39]. Of these, in a small
randomized, double-blind study, addition of
10% urea to the vehicle was significantly more
effective regarding epidermal proliferation,
stratum corneum hydration, and epidermal
thickness with a 60% reduction of the clinical
psoriasis severity score of scaling and a 32%
reduction of induration (see Table 3) compared
to the vehicle alone [38]. The ointment base
also improved psoriasis, but urea was
significantly more effective showing a 40%
reduction in epidermal proliferation compared
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to the vehicle [38]. Similar results were
demonstrated in a double-blind, placebo-
controlled study, in which two urea gel
formulations (10% plain urea gel or 5% urea
niosomal gel) produced a reduction in
erythema, infiltration, and desquamation, as
well as in the total psoriasis area and severity
index (PASI) score, with the 5% urea niosomal
gel being more effective regarding
desquamation compared to the plain gel and
placebo. However, the percentage of affected
area was not influenced [42]. From three small
studies, limited evidence is known for an
enhanced efficacy of other topical agents such
as bifonazole, dithranol or betamethasone
dipropionate and calcipotriol leading to a
shortened treatment duration (see Table 3)
[43–45]. In the evaluated clinical studies, a
burning sensation was observed in three
patients (see Table 3) [39, 42].
Alpha-Hydroxy Acids and Poly-Hydroxy
Acids
Alpha-hydroxy acids (AHAs), most notably
glycolic acid and lactic acid, are used in
chemical-peel solutions to exfoliate thickened
skin in hyperkeratotic conditions. However,
their use in the treatment of psoriasis has only
recently been advocated and, thus, they are not
mentioned as keratolytic agents in relevant
psoriasis guidelines [7, 17]. AHAs penetrate the
epidermis, inducing an increase in stratum
corneum turnover and cause desquamation of
the outermost layer without impairing barrier
function [21]. They reduce intercorneocyte
bonds by increasing the distance between
corneocytes due to increased stratum corneum
water content, by reducing the charges on the
surface of cells, by inhibiting enzymes involved
in the cohesion between corneocytes, and by
breaking desmosomes as they diminish the pH
of the medium. This reduction can also degrade
keratinocytes directly, thus promoting cell
proliferation. In the dermis, AHAs can
stimulate the biosynthesis of
glycosaminoglycans, collagen, and other
substances, which cause thickening of the skin
[47]. Poly-hydroxy acids (PHAs) also aid in
dermal expansion and can provide the
components for glycosaminoglycans. PHAs
have anti-oxidant and moisturizing properties
and may provide protection of psoriatic skin
with a disrupted skin barrier. When used in
combination with topical corticosteroids, AHAs
or PHAs exert a synergistic effect and reduce
steroid-induced skin atrophy [3].
For AHAs and PHAs, results from 3 small
clinical studies including 57 patients in total are
available. One of these trials, a small, controlled
study, demonstrated that glycolic acid in
monotherapy may lead to significant
reduction in hyperkeratosis and erythema as
compared to baseline, which was comparable to
that achieved with 0.05% betamethasone
valerate (see Table 4) [3, 47, 48]. In a small,
short-term study, AHA/PHA and salicylic acid
exhibited similar efficacy with regard to the
reduction of scaling when compared to baseline
(see Table 4) [3]. The third small study found a
synergistic effect of 10% glycolic acid in
combination with topical corticosteroids
leading to reduced treatment duration and an
increased healing rate (see Table 4) [48]. In the
evaluated studies, no treatment-related adverse
events were reported (see Table 4).
Salicylic Acid
Salicylic acid is the most commonly used and
most thoroughly studied of the currently
known keratolytic compounds [21]. In
concentrations of 5% and above, it exerts an
increasingly potent, rapid, and deep keratolytic
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effect on the stratum corneum which leads to
descaling [31]. As a mechanism of action, it is
suggested that salicylic acid reduces
intercellular cohesion between corneocytes by
dissolving the intercellular cement material and
reducing the pH of the stratum corneum,
thereby increasing hydration and softening [3,
7, 31]. Topical salicylates also reduce pruritus
[26] and, at concentrations of C0.3%, they
possess bacteriostatic and bactericidal activity
against yeast and Gram-negative and Gram-
positive bacteria [22]. In their clinical guide,
Naldi and Rzany [9] state that there is consensus
that salicylic acid is an effective initial and
adjunctive treatment in chronic plaque
psoriasis. It is most beneficial in extremely
thick or scaly psoriatic plaques [22]. According
to current guidelines, salicylic acid promotes
skin availability of other topical therapies
including topical corticosteroids due to its
keratolytic and penetration-enhancing effect
[1, 7, 14, 20, 49]. This leads to improved
efficacy of other topical treatments. While
salicylic acid is commonly applied and
effective when used as a pre-treatment before
phototherapy [15, 16], topically administered
salicylic acid, in concentrations C0.1%, is
photoprotective [31]. Thus, application of
salicylic acid before UVB phototherapy is not
recommended [15, 16, 22, 32, 50, 51].
According to the evaluated reviews, topical use
of salicylic acid is limited by the risk of chronic
or acute systemic intoxication [2, 7] with
symptoms such as oral pain, headache, central
nervous system symptoms, dizziness, metabolic
acidosis, tinnitus, nausea, vomiting, and gastric
symptoms, as well as hyperventilation [2, 3, 52].
These symptoms may occur after prolonged
topical treatment of large body surfaces (i.e.,
[20%) [6, 7, 25], especially in children under
12 years of age and in patients with significant
renal or hepatic impairment [2, 3, 7, 22, 25].
Local irritation such as stinging, burning, dry
skin, peeling, scaling, or contact dermatitis was
also reported [1, 9, 53]. Temporary shedding of
telogen hair has been observed when used in
the treatment of scalp psoriasis [26].
Concomitant use of other drugs, which may
contribute to elevated serum salicylate levels,
should be avoided [7]. There is an increased risk
for developing toxicity to other topically
applied agents used concurrently, as salicylic
acid may increase their skin penetration [3]. In
addition, topical use of salicylic acid can reduce
the efficacy of calcipotriol [2].
Monotherapy
Regarding monotherapy, three studies on
salicylic acid including 65 patients were
evaluated [54–56]. Of these, an open-label, pilot
study demonstrated that 6% salicylic acid used as
a monotherapy was highly effective, well
tolerated, and acceptable in 10 patients with
scalp psoriasis [54]. All psoriasis severity
parameters as well as the percentage of affected
area were reduced with a significant decrease
in Psoriasis Scalp Severity Index score from
15.3 to 3.0 after 4 weeks of monotherapy when
compared to baseline (P\0.001). A total of 60%
of patients were either ‘‘completely cleared’’ or
‘‘almost cleared’’ (see Table 5) [54]. In a
randomized, double-blind study in 25 patients
investigating 6% salicylic acid vs. 20% AHA/PHA
cream (see also Table 4), both topical agents
resulted in significant improvement of scaling,
erythema, and induration, as well as investigator
global assessment, at the end of week 1 and 2 and
exhibited similar efficacy in reducing scaling.
However, the extent of affected area was not
investigated in this study (see Table 5) [3].
Similar results were obtained in an earlier,
randomized controlled trial reporting successful
treatment of moderate or severe scalp psoriasis
with 6% salicylic acid in 30 patients, including
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10 in-patients and 20 out-patients [55]. In-
patients were treated for 3 weeks with daily
applications of 6% salicylic acid removed with a
shampoo 24 h later. Out-patients were treated
for 6 weeks with salicylic acid applied once daily
and removed 12 h later. If progress was slow, a
shampoo containing 3% coal tar solution was
substituted for the shampoo. As a result, 90% of
in-patients and 65% of out-patients improved
with salicylic acid regarding scaling and
percentage of affected area and in one patient,
the scalp cleared completely. Scaling scores for
out-patients improved from baseline 7.0 to 4.5 at
6 weeks (n = 20; P\0.01) and the scores for in-
patients improved from baseline 7.7 to a score of
3.7 at 3 weeks (n = 10; P\0.001). Eight of the
out-patients, but none of the in-patients used the
coal tar shampoo. Out-patients used less salicylic
acid (27 g weekly) than in-patients (72 g weekly;
see Table 5) [55].
Combination Therapy
Concerning combination therapy with the super-
potent or potent corticosteroids betamethasone
dipropionateandmometasonefuroate,5randomized
controlled trials in a total of 1,248 patients were
identified. Patients with psoriasis were treated for
up to 3 weeks with a combination of 2% salicylic
acid and 0.05% betamethasone dipropionate
(2 studies; n = 72) or 5% salicylic acid and 0.1%
mometasonefuroate (3 studies; n = 519). The
respective control groups received the
corresponding corticosteroid only. In one
study, a more rapid onset of action and a more
rapid clearing of scaling, pruritus, and
inflammation was demonstrated with the
combination [56]; whereas in another trial, the
combination was statistically more effective than
the respective corticosteroid alone in terms of
mean total disease sign scores beginning at day 8
(P = 0.05) and continuing through days 15 and
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individual sign scores: the combination was
significantly more effective than the
corticosteroid alone for scaling starting on day
8 (P = 0.01), erythema (P\0.02), and pruritus on
day 14 (P\0.01) as well as induration on day 15
(P = 0.03), with P B 0.01 for all three signs of
psoriasis (erythema, induration and scaling) at
day 22 [46, 57]. According to the investigators’
global evaluation of overall clinical response,
patients treated with the combination showed a
better progress than those treated with the
corticosteroid alone (P\0.01) [46]. After 7 days
of treatment, a significantly greater reduction of
the Psoriasis Area Severity Index score was
observed compared to the corticosteroid alone
(P = 0.0017). Regarding the items of the
Dermatology Life Quality Index (DLQI)
questionnaire, data showed significant
differences in the ‘symptoms and feelings’
(P = 0.0464) and the ‘personal relationships’
items (P = 0.0378) [58]. On the self-assessment
questionnaire, patients preferred the
combination over the corticosteroid alone for
overall improvement of general appearance and
overall improvement of psoriasis (both P = 0.03;
see Table 5) [59]. In the evaluated studies, no
systemic toxicity was observed and absorption of
salicylate was negligible after application of 6%
to the scalp [55]. Yet application-site reactions
such as dryness, irritation, burning, pruritus, and
skin atrophy were reported (see Table 5) [46, 55,
58, 59].
DISCUSSION
This systematic literature review covering
articles published from January 1983 to
December 2013 identified several reviews,
meta-analyses, and guidelines emphasizing
that, while topical treatment with
corticosteroids and vitamin D analogs currently
represent first-line therapies, adjuvant therapy
with topical keratolytics and emollients forms
part of an integrated therapeutic concept. This is
in line with the evaluated studies demonstrating
specific properties of these agents that determine
their role within this concept.
Regarding emollients, the evaluated studies
provided some evidence that these agents play a
role as a basic therapy in supporting skin care
and improving the altered structure and
function of the skin but without a distinct
clinical response in psoriasis. Study results for
urea point to a reduction of induration and/or
scaling. However, the percentage of affected
area was not reduced. Due to its emollient and
keratolytic activity, urea may be used as a safe
basic therapy leading to increased patient
satisfaction. The same applies to AHAs and
PHAs. However, to date, there are only a
limited number of short-term studies regarding
the mentioned substances, which were mostly
performed in small populations without control
or a clear randomization procedure and mainly
using weak outcomes variables.
Salicylic acid represents the best studied
keratolytic compound to date. Although
salicylic acid used as monotherapy induced a
significant improvement of psoriasis, as
determined by the percentage of body surface
area involved and/or the overall degree of
erythema, induration, and desquamation [3,
55], the evidence of its efficacy as monotherapy
remains controversial due to the lack of larger,
high-quality trials and the absence of a placebo
control which is considered a major limitation
of most of the identified studies.
Only four of the studies included in this
review had a placebo control, that is, a
comparison with the cream vehicle. In three
of these studies, treatment with the active
14 Dermatol Ther (Heidelb) (2015) 5:1–18
substance (i.e., urea) led to a statistically
significant improvement of outcome
parameters compared to the vehicle [41]. In
two studies, the ointment base (which was not
further specified) also improved psoriasis, but
to a significantly lesser extent than the
pharmacologically active ingredient, urea [38,
42]. This is in line with the studies on
emollients, that may represent constituents
of an ointment base and that did not show
any relevant reduction in the severity of
psoriasis.
As regards its place in therapy, results of
the current literature analysis support the use
of salicylic acid as monotherapy in the
treatment of scalp psoriasis and as an
adjuvant agent in the treatment of other
skin areas affected by psoriasis. Yet, patient
adherence in scalp psoriasis is often poor due
to the longer contact times required and since
vehicles tend to be greasy [11]. In
combination with the super-potent or potent
corticosteroids betamethasone dipropionate
and mometasonefuroate, evidence from
several randomized controlled trials in a total
of 1,248 patients demonstrates that addition
of salicylic acid is beneficial in inducing a
more rapid onset of action and a reduction of
psoriasis determined by the percentage of
body surface area involved and/or the overall
degree of erythema, induration, and
desquamation. The addition of salicylic acid
led to a better investigators’ global evaluation
of overall clinical response, a more favorable
evaluation by patients and significant lower
DLQI scores compared to the respective
corticosteroid alone.
Since treatment outcome determines
treatment satisfaction, which in turn affects
medication adherence, keratolytic agents such
as salicylic acid may support overall adherence
to the prescribed therapy. While salicylic acid at
the applied concentrations was well tolerated in
the evaluated studies with no signs of systemic
toxicity, concerns of systemic toxicity are
consistently expressed in the literature [2, 3, 6,
7, 22, 27].
CONCLUSION
Considering that descaling and/or penetration
enhancement entails a distinct benefit in
patients with psoriasis improving patient
satisfaction and treatment adherence, there
still is a need for well-designed studies on the
currently available keratolytic agents but also
on suitable keratolytic alternatives to salicylic
acid with less potential for adverse effects. Cost-
effectiveness should also be addressed in future
studies.
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